|
Jun 24
|
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
|
|
Jun 19
|
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
|
Jun 19
|
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
|
|
Jun 19
|
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
|
|
Jun 18
|
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
|
|
Feb 16
|
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
|
|
Feb 13
|
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
|
|
Feb 12
|
Here's Why Ligand Pharmaceuticals (LGND) Fell More Than Broader Market
|
|
Jan 11
|
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Jan 11
|
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
|
|
Dec 1
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
|
Dec 1
|
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
|
|
Nov 28
|
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
|
|
Nov 28
|
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
|
|
Nov 28
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Sep 8
|
Novan reaches deals to sell assets in bankruptcy case
|